Therapeutics News and Research

RSS

Amsterdam Molecular first half 2010 net loss in line with last year

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today reported its results for the first half year of 2010.

31 Aug 2010

Cell Therapy Foundation analysis calls for funding in medical research

Some of the most promising medical research conducted to treat diseases of the brain, heart, and circulatory system is moving too slowly to help millions of patients, according to the Cell Therapy Foundation, which advocates the use of adult stem cells to dramatically impact and improve the condition of patients who suffer from a variety of conditions.

31 Aug 2010

Trius commences oral torezolid phosphate Phase 3 clinical study for ABSSSI

Trius Therapeutics, Inc. announced that the first patient has been dosed in its Phase 3 clinical study of the oral dosage form of torezolid phosphate for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The double-blind, active control, pivotal study is designed to compare the efficacy and safety of once-daily oral administration of 200 milligrams of torezolid phosphate for six days of treatment with the efficacy and safety of twice-daily oral administration of 600 milligrams of linezolid (Zyvox®) for 10 days of treatment.

30 Aug 2010

23rd ECNP Press conference on impact of circadian rhythms on human brain

All humans are synchronised to the rhythmic light-dark changes that occur on a daily basis. Rhythms in physiological and biochemical processes and behavioural patterns persist in the absence of all external 24-hour signals from the physical environment, with a period that is close to 24 hours

30 Aug 2010

Orexigen Therapeutics board approves grant of inducement stock options

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that on August 25, 2010 the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 10,000 shares of common stock to two new employees.

27 Aug 2010

David Mosser to discuss primary duty of macrophages at American Physiological Society conference

The term "macrophage" conjures images of a hungry white blood cell gobbling invading bacteria. However, macrophages do much more than that. Not only do they act as antimicrobial warriors, they also play critical roles in immune regulation and wound-healing. They can respond to a variety of cellular signals and change their physiology in response to local cues.

27 Aug 2010

Increase in regeneration of nerve cells can alleviate or prevent memory loss

Production of new nerve cells in the human brain is linked to learning and memory, according to a new study from the University of Florida. The research is the first to show such a link in humans. The findings, published online and in an upcoming print issue of the journal Brain, provide clues about processes involved in age- and health-related memory loss and reveal potential cellular targets for drug therapy.

27 Aug 2010

Experimental drug PLX4032 holds promise against cancers with faulty BRAF gene

An experimental drug designed to treat cancers with a particular genetic fault has shown promising results in a small clinical trial.

27 Aug 2010

FDA approves Chelsea Therapeutics' Phase II protocol for CH-4051 antifolate in rheumatoid arthritis

Chelsea Therapeutics International, Ltd. announced confirmation by the U.S. Food and Drug Administration (FDA) that its proposed Phase II protocol for CH-4051 in rheumatoid arthritis has been approved by the agency.

26 Aug 2010

Treating metastatic melanoma tumors with specific genetic signature shows promising results

Use of an experimental targeted drug to treat metastatic melanoma tumors with a specific genetic signature was successful in more than 80 percent of patients in a phase 1 clinical trial.

26 Aug 2010

Bioniche, University of Ottawa sign global technology license agreement for botanical therapeutics

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, together with the University of Ottawa, one of Canada's top ten research universities, today announced the signing of an exclusive global license agreement. The agreement provides commercial access for Bioniche to University of Ottawa's technology for botanical therapeutics (natural health) and pharmaceutical compounds for treating anxiety and related conditions in animal health, human health and aquaculture

25 Aug 2010

Guided Therapeutics receives fund to commercialize LightTouch for cervical cancer detection

Guided Therapeutics, Inc. today announced that it was awarded $1.0 million to fund the second year of a $2.5 million grant from the National Cancer Institute (NCI) announced in 2009.

25 Aug 2010

3Sbio, Isotechnika Pharma sign development and commercialization agreement for voclosporin inhibitor

Isotechnika Pharma Inc., a biopharmaceutical company focused on the discovery and development of immune modulating therapeutics, and 3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced the signing of a development and commercialization agreement for voclosporin, a next generation calcineurin inhibitor being developed for use in the prevention of organ rejection following transplantation and the treatment of autoimmune diseases.

25 Aug 2010

Kamada, Baxter enter distribution and manufacturing agreement for Glassia Alpha-1 Antitrypsin Product

Kamada, Ltd., a biopharmaceutical company engaged in development, production and marketing of specialty life-saving therapeutics and Baxter International Inc., a global, diversified healthcare company announced today that they have entered into an exclusive distribution and manufacturing agreement for Kamada's liquid, ready to use, intravenous Alpha-1 Antitrypsin Product for the treatment of hereditary Alpha-1 Antitrypsin Deficiency approved by the USFDA on July 1st, 2010 for marketing under the trade name "Glassia™".

From Baxter International Inc. 25 Aug 2010

Researchers identify novel approach to decrease glioblastoma multiforme recurrence

Researchers from the University of Massachusetts Medical School have identified a novel approach of combining chemotherapy with a targeted therapy to decrease the recurrence of glioblastoma multiforme, the most common and aggressive brain tumor.

25 Aug 2010

Echo Therapeutics completes clinical study of Prelude SkinPrep System

Echo Therapeutics, Inc., a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude SkinPrep System for transdermal drug delivery, today announced the completion of a clinical study of Prelude.

25 Aug 2010

Ensemble Therapeutics showcases data on new drug discovery platform at ACS National Meeting

Ensemble Therapeutics announced today the presentation of data on its macrocyclic-based drug discovery platform at the American Chemical Society National Meeting August 22-26, in Boston at the Boston Convention and Exposition Center.

24 Aug 2010

Alnylam Pharmaceuticals to present results on RNAi therapeutics at ACS National Meeting

Alnylam Pharmaceuticals, Inc.,a leading RNAi therapeutics company, announced today that it will make a total of 16 oral presentations at the American Chemical Society (ACS) Fall 2010 240th National Meeting & Exposition being held in Boston, Mass. from August 22-26, 2010.

24 Aug 2010

3SBio and Isotechnika enter strategic agreement for voclosporin in China

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products and Isotechnika Pharma Inc., a biopharmaceutical company focused on the discovery and development of immune modulating therapeutics, today announced the signing of a development and commercialization agreement for voclosporin.

24 Aug 2010

Aileron Therapeutics, Roche partner to develop, commercialise Stapled Peptide Therapeutics

Aileron Therapeutics and Roche announced today that they have entered into a collaboration to discover, develop and commercialise a new class of drugs called Stapled Peptide Therapeutics. As part of this agreement, Roche will work with Aileron to develop drug candidates against up to five undisclosed targets selected from Roche's key therapeutic areas, which include oncology, virology, inflammation, metabolism and CNS.

24 Aug 2010

Therapeutics News and Research

Amsterdam Molecular first half 2010 net loss in line with last year

Cell Therapy Foundation analysis calls for funding in medical research

Trius commences oral torezolid phosphate Phase 3 clinical study for ABSSSI

23rd ECNP Press conference on impact of circadian rhythms on human brain

Orexigen Therapeutics board approves grant of inducement stock options

David Mosser to discuss primary duty of macrophages at American Physiological Society conference

Increase in regeneration of nerve cells can alleviate or prevent memory loss

Experimental drug PLX4032 holds promise against cancers with faulty BRAF gene

FDA approves Chelsea Therapeutics' Phase II protocol for CH-4051 antifolate in rheumatoid arthritis

Treating metastatic melanoma tumors with specific genetic signature shows promising results

Bioniche, University of Ottawa sign global technology license agreement for botanical therapeutics

Guided Therapeutics receives fund to commercialize LightTouch for cervical cancer detection

3Sbio, Isotechnika Pharma sign development and commercialization agreement for voclosporin inhibitor

Kamada, Baxter enter distribution and manufacturing agreement for Glassia Alpha-1 Antitrypsin Product

Researchers identify novel approach to decrease glioblastoma multiforme recurrence

Echo Therapeutics completes clinical study of Prelude SkinPrep System

Ensemble Therapeutics showcases data on new drug discovery platform at ACS National Meeting

Alnylam Pharmaceuticals to present results on RNAi therapeutics at ACS National Meeting

3SBio and Isotechnika enter strategic agreement for voclosporin in China

Aileron Therapeutics, Roche partner to develop, commercialise Stapled Peptide Therapeutics

Industry Focus eBook - Microbiome (1st edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News